Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

GlaxoSmithKline to look for early-stage assets - CEO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/08/2019 | 12:12pm EST
FILE PHOTO: GlaxoSmithKline CEO, Emma Walmsley, arrives for a meeting in Downing Street in central London

(Reuters) - GlaxoSmithKline Plc will actively look to buy early-stage assets and partner with companies, the drugmaker's chief executive officer said on Tuesday.

Britain's biggest drugmaker is also likely to evaluate licensing deals and would continue to invest in early-stage HIV treatments, CEO Emma Walmsley said at the JP Morgan healthcare conference in San Francisco.

Walmsley said the company had extensive plans for its experimental drug to treat multiple myeloma, which targets a protein called BCMA, adding that it could be launched by 2020.

On the company's portfolio of cancer medicines, she said GlaxoSmithKline had almost doubled the size of its immuno-oncology pipeline over the past few months.

The company's plan to acquire U.S.-based Tesaro for $5.1 billion (£4 billion) in December is among several large healthcare deals in recent months to pump money into cancer drug development.

That was followed by Bristol-Myers Squibb Co's $74 billion deal to buy Celgene Corp and Eli Lilly & Co's $8 billion acquisition of Loxo Oncology earlier this month.

In what was widely considered a bold move on Walmsley's part, last month GlaxoSmithKline also said it would split into two businesses after forming a new joint venture with Pfizer consumer health division.

(Reporting by Tamara Mathias in Bengaluru; Editing by Arun Koyyur)

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY -1.19% 49.13 Delayed Quote.-4.35%
CELGENE CORPORATION -1.05% 87.3 Delayed Quote.36.21%
ELI LILLY AND COMPANY -0.25% 116.8 Delayed Quote.1.18%
GLAXOSMITHKLINE -1.60% 1484.4 Delayed Quote.-0.46%
LOXO ONCOLOGY INC -0.18% 233.26 Delayed Quote.66.53%
PFIZER -1.45% 42.11 Delayed Quote.-2.11%
TESARO INC 0.03% 74.88 Delayed Quote.0.85%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
01/16GLAXOSMITHKLINE : Two positive phase III studies of tafenoquine for the radical ..
PU
01/15Drug companies greet 2019 with U.S. price hikes
RE
01/15British shares up on China stimulus hopes, all eyes on Brexit deal vote
RE
01/15GLAXOSMITHKLINE : Extends Tender Offer for TESARO
PU
01/15GLAXOSMITHKLINE : GlaxoSmithKline Extends Tender Offer for TESARO
DJ
01/11LONDON STOCK EXCHANGE : FTSE dips as sterling firms on report of potential Brexi..
RE
01/10MANAGEMENT TRACKS : Tak joins Flagship, Evercore taps Mehrotra
AQ
01/09UK shares jump on trade hope; Taylor Wimpey triggers house-builder rally
RE
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/03Vectura hopes new respiratory device will breathe life into business
RE
More news
Financials (GBP)
Sales 2018 30 588 M
EBIT 2018 8 444 M
Net income 2018 3 728 M
Debt 2018 21 003 M
Yield 2018 5,39%
P/E ratio 2018 20,85
P/E ratio 2019 15,90
EV / Sales 2018 3,10x
EV / Sales 2019 3,04x
Capitalization 73 692 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 16,4  GBP
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Paul Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE-0.46%94 875
JOHNSON & JOHNSON-0.78%344 044
PFIZER-2.11%245 746
NOVARTIS3.55%221 313
ROCHE HOLDING LTD.5.59%220 097
MERCK AND COMPANY-2.50%190 790